Clinical Trial Update: Imaging of Solid Tumors Using DLL3 SPECT [EARLY_Phase 1]

View source ↗

Summary

Early Phase 1 clinical trial evaluating DLL3 SPECT imaging for solid tumors, including castration-resistant prostate cancer and neuroendocrine tumors; currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Neuroendocrine Tumors
• Solid Tumors

Drugs mentioned

• DLL3 SPECT imaging agent

Snippet

Sponsor: Thomas Hope | Conditions: Solid Tumor Cancer, Castration Resistant Prostate Cancer | EARLY_Phase 1 | Status: NOT_YET_RECRUITING